In recent years, to improve risk assessment additional prognostic indicators such as gene-expression signatures [21-23], combined genomic and molecular signatures [24] or expression levels of single candidate genes, e.g., Trk (NTRK) family of neurotrophin receptors [25,26], FYN [27], PRAME [28] and ZNF423 [29], have been associated with NB clinical behavior. This evidence concerns the gene PRAME and neuroblastoma.